See the DrugPatentWatch profile for tigecycline

Tigecycline, a broad-spectrum antibiotic, has been impacted by patent expiration, which in turn has influenced the diversity of the antibiotic market. Tigecycline's patent expiration has allowed for the emergence of generic alternatives, increasing competition and affordability in the antibiotic market.

Tigecycline, developed by Wyeth Pharmaceuticals (now Pfizer), received approval from the US Food and Drug Administration (FDA) in 2005 for treating various bacterial infections. Its patent expired in 2015 [1], leading to the introduction of generic versions.

The entry of generic tigecycline into the market has resulted in increased competition among manufacturers, driving down prices and making the antibiotic more accessible to patients and healthcare providers [2]. This has contributed to the diversity of the antibiotic market by offering more options for treatment and promoting competition among pharmaceutical companies.

Furthermore, the availability of generic tigecycline has encouraged research and development of new antibiotics, as pharmaceutical companies seek to differentiate their products and maintain a competitive edge [3]. This has led to the development of novel antibiotics with improved efficacy, safety, and resistance profiles, further enhancing the diversity of the antibiotic market.

In summary, tigecycline's patent expiration has had a positive impact on the antibiotic market by increasing competition, reducing prices, and promoting the development of new antibiotics. This has resulted in a more diverse antibiotic market, benefiting patients, healthcare providers, and the pharmaceutical industry.

Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/patent/tigecycline-tygacil/
[2] US Food and Drug Administration. (2017, April 13). FDA approves first generic of Tygacil to treat certain serious bacterial infections. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-tygacil-treat-certain-serious-bacterial-infections
[3] World Health Organization. (2019, February 27). WHO list of critically important antimicrobials for human medicine, 6th revision. Retrieved from https://www.who.int/news-room/detail/27-02-2019-who-publishes-6th-list-of-critically-important-antimicrobials-for-human-medicine